Merck Cash Flow from Operating Activities 2010-2025 | MKKGY

Merck cash flow from operating activities for the twelve months ending March 31, 2025 was $11.279B, a 15.1% increase year-over-year.

  • Merck annual cash flow from operating activities for 2024 was $4.963B, a 21.17% increase from 2023.
  • Merck annual cash flow from operating activities for 2023 was $4.095B, a 8.73% decline from 2022.
  • Merck annual cash flow from operating activities for 2022 was $4.487B, a 17.83% decline from 2021.

Merck Cash Flow from Operating Activities 2010-2025 | MKKGY

  • Merck annual cash flow from operating activities for 2024 was $4.963B, a 21.17% increase from 2023.
  • Merck annual cash flow from operating activities for 2023 was $4.095B, a 8.73% decline from 2022.
  • Merck annual cash flow from operating activities for 2022 was $4.487B, a 17.83% decline from 2021.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$75.5B
Zoetis (ZTS)$67.5B
Takeda Pharmaceutical (TAK)$46.8B
Daiichi Sankyo, - (DSNKY)$44.2B
BeOne Medicines - (ONC)$30.6B
Sandoz Group AG (SDZNY)$24.9B
Summit Therapeutics (SMMT)$21B
Shionogi (SGIOY)$14.2B
United Therapeutics (UTHR)$13.4B
Neurocrine Biosciences (NBIX)$13.2B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.2B
Stevanato Group S.p.A (STVN)$7.7B
Corcept Therapeutics (CORT)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.7B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.8B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.3B
Hypermarcas (HYPMY)$3.2B
Crinetics Pharmaceuticals (CRNX)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.3B
Centessa Pharmaceuticals (CNTA)$2.1B
BioCryst Pharmaceuticals (BCRX)$1.8B
Ocular Therapeutix (OCUL)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B
Endo (NDOI)$1.6B